1. Israel Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Evogene Ltd.

Evogene Ltd.

EVGN
Evogene Ltd.US flagNASDAQ Global Market
0.54
USD
-0.01
- -
4.63MMarket Cap
Evogene Ltd.
EVGN
(NASDAQ Global Market)

Recent

price

0.54

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
8.51
9.27
8.91
5.79
4.4
2.57
1.31
0.68
0.29
0.37
0.23
0.41
0.65
0.98
0.49
0.21
Revenue per Share
0.37
-1.37
-4.5
-5.8
-6.8
-7.7
-8.1
-8.06
-7.03
-8.3
-6.87
-6.46
-5.23
-2.89
-1.08
-1.37
Basic EPS, GAAP
-0.93
-2.63
-3.49
-4.97
-5.69
-4.91
-6.42
-6.03
-7.21
-7.17
-6.32
-6.03
-4.85
-3.57
-1.73
-1.31
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
0.02
Dividend per Share
- -
- -
50.1
45.79
40.84
34.26
26.94
19.43
19.47
12.93
13.03
6.77
2.38
-0.22
-0.01
-0.24
Book Value per Share
- -
- -
50.08
45.79
40.84
34.26
26.94
19.43
12.84
8.4
9.34
3.34
-0.22
-2.09
-0.01
-0.24
Tangible Book Value per Share
2
2
2
3
3
3
3
3
3
3
4
4
5
6
8
9
Basic Weighted Avg Shares
15
17
18
15
11
7
3
2
1
1
1
2
3
6
4
2
Sales/Revenue/Turnover
-21.36
-18.31
-49.6
-105.13
-161.03
-322.46
-649.13
-1,144.19
-2,810.89
-2,385.96
-3,328.28
-1,608.42
-744.63
-336.33
-364.24
-767.73
Operating Margin (%)
1
2
2
2
2
2
2
2
3
3
2
3
1
1
1
1
Depreciation Expense
1
-3
-9
-15
-17
-20
-21
-21
-18
-23
-28
-27
-24
-16
-8
-12
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
4.33
-14.77
-50.5
-100.13
-154.67
-299.57
-616.33
-1,188.21
-2,405.31
-2,247.5
-2,988.49
-1,590.33
-800.77
-295.59
-220.22
-638.12
Profit Margin (%)
- -
48
121
110
99
84
68
50
43
42
50
32
28
3
12
10
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
2
2
2
11
11
2
1
1
LT Debt
- -
48
125
116
104
87
69
50
60
57
63
35
29
15
12
8
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
-10.45
-10.26
-12.07
-15.66
-20.51
-26.6
-34.76
-36.15
-48.6
-55.75
-65.3
-119.45
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
1
1
1
LT Borrowings
- -
- -
- -
LT Finance Leases
2
1
1
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
9
9
10
Market Capitalization
10
10
8

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
21
16
15
Cash, Cash Equivalents & STI
16
13
13
Accounts Receivable, Net
- -
- -
- -
Inventories
2
- -
- -
Total Current Liabilities
4
3
5
Payables & Accruals
2
2
3
ST Debt
1
1
1
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-16.85%
-23.75%
-19.3%
Free Cash Flow
1.3%
-5.65%
-32.91%
Net Income, GAAP
-3.9%
-15.02%
-48.53%
Sales/Revenue/Turnover
4.7%
40.73%
-30.91%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
4
1
2
2
6
2025
2
1
- -
- -
4
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.76
-1.06
-1.31
0.06
-2.89
2025
-0.38
-0.62
0.44
-0.61
-1.08
2026
-0.6
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
0.02
- -
- -
- -
- -
Similar Companies
Abpro Holdings Inc (ABPWW)
PYC Therapeutics Limited (PYC.AX)
Spyre Therapeutics, Inc. (SYRE)
Karolinska Development AB (publ) (KDEVF)
LakeShore Biopharma Co., Ltd. (LSBPW)
GC Genome Corporation (340450.KQ)
Business
Evogene Ltd. (NASDAQ: EVGN; TASE: EVGN.TA) operates as a computational biology company that leverages artificial intelligence, machine learning, and big data through its Computational Predictive Biology (CPB) platform to discover and develop life-science products based on microbes, small molecules, and genetic elements; the company serves industries including human health, agriculture, and industrial applications. It maintains three core technological engines--MicroBoost AI for microbe-based products such as human microbiome therapeutics via subsidiary Biomica Ltd., ag-biologicals, and industrial microbes; ChemPass AI for small molecule-based products including pharmaceuticals and ag-chemicals via subsidiary AgPlenus Ltd.; and GeneRator AI for genetic element-based products such as seed traits and castor ag-solutions via subsidiary Casterra Ag Ltd.--with operations spanning Israel, the United States, Brazil, and internationally. Founded in 1999 and headquartered in Rehovot, Israel, Evogene targets pharmaceutical developers, agricultural companies, and industrial firms with predictive solutions that accelerate product development while reducing costs and risks. In a significant strategic shift, the company completed the divestiture of the majority of its ag-biologicals subsidiary Lavie Bio Ltd.'s activities and assets--including the proprietary Biology Driven Design platform, microbial bank, product pipeline, and MicroBoost AI for AG tech-engine--to ICL Group Ltd. in July 2025, pursuant to an agreement announced in April 2025, enabling focus on core platforms and unlocking subsidiary value while Lavie Bio retains certain partnerships for potential future revenue.

Company News

Company News APIChatGPT

  • prnewswire.com

    Evogene Responds to Dissident Shareholders: Transformation and Commercial Progress Provide a Clear Path Forward

  • seekingalpha.com

    EverGen Infrastructure Corp. (EVGN:CA) Q2 2026 Earnings Call Transcript

  • businesswire.com

    EverGen Infrastructure Reports Q2 2026 Results

  • businesswire.com

    EverGen Infrastructure Announces Voting Results for the Annual General Meeting of Shareholders Held on August 25, 2026

  • seekingalpha.com

    EverGen Infrastructure Corp. (EVGN:CA) Shareholder/Analyst Call Prepared Remarks Transcript

  • prnewswire.com

    Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Evogene Ltd. Shareholders Vote "FOR" the Company's Slate of Highly Qualified Director Nominees

  • seekingalpha.com

    Evogene Ltd. (EVGN) Q2 2026 Earnings Call Transcript

  • prnewswire.com

    Evogene Reports Second Quarter and First Half 2026 Financial Results

  • prnewswire.com

    Evogene Chairman Nir Nimrodi to Join Quarterly Results Call to Address Current Dissident Shareholders Situation

  • defenseworld.net

    Evogene (NASDAQ:EVGN) Stock Price Passes Below 200 Day Moving Average – Here’s Why

  • prnewswire.com

    Evogene Schedules Second Quarter 2026 Financial Results Release

  • prnewswire.com

    Evogene Ltd. and ELEO Inc. Announce Collaboration to Develop Next-Generation Oral Small-Molecule PCSK9 Pathway Inhibitors for Hyperlipidemia and Cardiovascular Diseases

  • prnewswire.com

    AgPlenus Launches Novel AI Model for Predicting Antifungal Potency, Expanding ChemPass AI for Ag™ Capabilities

  • prnewswire.com

    Evogene and Tel Aviv University's Blavatnik Center for Drug Discovery Announce Joint Initiative to Accelerate AI-Driven Small-Molecule Drug Discovery

  • businesswire.com

    EverGen Infrastructure Announces Share Issuance to Officers and Directors of the Company

  • prnewswire.com

    Evogene Announces Major Milestone in Its Collaboration with Google Cloud, Advancing ChemPass AI™ Toward Autonomous Small Molecule Discovery and Optimization

  • prnewswire.com

    Evogene to Present Its Pharma Division Achievements at the BIO International Convention

  • prnewswire.com

    Evogene Announces Successful Completion of Phase 1 Clinical Study of BMC128, a Rationally Designed Live Bacterial Product, in Combination with Nivolumab by its Subsidiary Biomica

  • seekingalpha.com

    EverGen Infrastructure Corp. (EVGN:CA) Q1 2026 Earnings Call Transcript

  • businesswire.com

    EverGen Infrastructure Reports Q1 2026 Results